Actionable news
All posts from Actionable news
Actionable news in MRK: MERCK & CO. Inc,

AstraZeneca lung cancer study fails in big setback for company

(Adds Tagrisso study, Merck alliance)

LONDON, July 27 (Reuters) - AstraZeneca's combination of two injectable immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday.

Initial results from the study, known as MYSTIC, found the combination was no more effective at stopping disease progression than chemotherapy in patients expressing a protein called PD-L1 on 25 percent or more of their cancer cells.

As a secondary endpoint, although not formally tested, Imfinzi monotherapy also would not have met a pre-specified threshold of progression-free survival benefit, the company...